Precision Biosciences (DTIL) EBITDA Margin (2018 - 2026)
Precision Biosciences' (DTIL) quarterly EBITDA Margin came in at 83.73% in Q1 2026, up 7616454.0% year-on-year from N/an in Q1 2025, and down 328.97% on a QoQ basis from 36.57% in Q4 2025.
Precision Biosciences (DTIL) EBITDA Margin (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has 9 years of EBITDA Margin data on file, last reported at 83.73% in Q1 2026.
- On a quarterly basis, EBITDA Margin rose 7616454.0% year-over-year to 83.73% in Q1 2026; TTM through Mar 2026 was 86.77%, a 57.0% decrease from a year earlier, with the FY2025 full-year figure at 152.19%, down 11411.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 83.73%, down from 36.57% in the prior quarter.
- Over the last five years, EBITDA Margin for DTIL reached as high as 48.39% in Q2 2024 and fell as low as 158976.92% in Q3 2025.
- Historically, EBITDA Margin has averaged 21574.1% across 5 years, with a median of 199.32% in 2022.
- Across the five-year window, EBITDA Margin tumbled 15528335 bps in 2025 and jumped 7616454 bps in 2026, its largest moves.
- Year by year, EBITDA Margin stood at 114.26% in 2022, then tumbled by 85 bps to 211.57% in 2023, then plunged by 1741 bps to 3894.36% in 2024, then soared by 101 bps to 36.57% in 2025, then plunged by 329 bps to 83.73% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 83.73% in Q1 2026, 36.57% in Q4 2025, and 158976.92% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Precision Biosciences | 178.85 Mn | 150.56 Mn | - | -83.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -83.73% |
| Dec 31, 2025 | 36.57% |
| Sep 30, 2025 | -158,976.92% |
| Jun 30, 2025 | -121,538.89% |
| Mar 31, 2025 | -76,248.28% |
| Dec 31, 2024 | -3,894.36% |
| Sep 30, 2024 | -3,693.58% |
| Jun 30, 2024 | 48.39% |
| Mar 31, 2024 | -23.81% |
| Dec 31, 2023 | -211.57% |
| Sep 30, 2023 | -94.23% |
| Jun 30, 2023 | -15.81% |
| Mar 31, 2023 | -152.10% |
| Dec 31, 2022 | -114.26% |
| Sep 30, 2022 | -199.32% |
| Jun 30, 2022 | -773.66% |
| Mar 31, 2022 | -824.09% |
| Dec 31, 2021 | -484.68% |
| Sep 30, 2021 | -48.02% |
| Jun 30, 2021 | 31.44% |